Clinical pharmacokinetics of tirofiban, a nonpeptide glycoprotein IIb/IIIa receptor antagonist: Comparison with the monoclonal antibody abciximab

Clinical Pharmacokinetics

Volumn 41, Issue 3, 2002, Pages 187-195

  Kondo, Kazunao ^a   Umemura, Kazuo ^a  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ENOXAPARIN; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MONOCLONAL ANTIBODY; TICLOPIDINE; TIROFIBAN; TYROSINE DERIVATIVE;

AREA UNDER THE CURVE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DISTRIBUTION VOLUME; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COMPETITION; DRUG DISTRIBUTION; DRUG EFFECT; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG RESEARCH; DRUG STRUCTURE; FOOD AND DRUG ADMINISTRATION; HUMAN; KIDNEY FUNCTION; PRIORITY JOURNAL; REVIEW;

EID: 0036228470     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200241030-00003     Document Type: Review

References (41)

1. Correlation between fibrinogen binding to human platelets and platelet aggregability
2. The platelet membrane glycoprotein IIb-IIIa complex
3. The effect of Arg-Gly-Asp-containing peptides on fibrinogen and von Willebrand factor binding to platelets
4. Interaction of AP-2, a monoclonal antibody specific for the human platelet glycoprotein IIb-IIIa complex, with intact platelets
5. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex
6. Echistatin. A potent platelet aggregation inhibitor from the venom of the viper, Echis carinatus
7. Characterization and platelet inhibitory activity of bitistatin, a potent arginine-glycine-aspartic acid-containing peptide from the venom of the viper Bitis arietans
8. Non-peptide fibrinogen receptor antagonists. I: Discovery and design of exosite inhibitors
9. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
10. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
11. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
12. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
13. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
14. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE Study
15. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
16. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention
17. An overview of the results of clinical trials with glycoprotein IIb/IIIa inhibitors
18. Tirofiban: An overview of the phase III trials
19. Newer antiplatelet agents in acute coronary syndromes
20. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
21. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction
22. Safe use of platelet GP IIb/IIIa inhibitors
23. Abciximab, eptifibatide, and tirofiban: Comparison of parenteral glycoprotein IIb/IIIa inhibitors
24. Differences among the parenteral platelet glycoprotein IIb/IIIa inhibitors and implications for treatment
25. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man
26. Pharmacokinetics and pharmacodynamics of MK-383, a selective non-peptide platelet glycoprotein-IIb/IIIa receptor antagonist, in healthy men
27. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty
28. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GPIIb/IIIa receptor blockade
29. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
30. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and 'clinical restenosis'
31. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins
32. Enhancement by ticlopidine of the inhibitory effect on in vitro platelet aggregation of the glycoprotein IIb/IIIa inhibitor tirofiban
33. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes
34. Determination of MK-383, a non-peptide fibrinogen receptor antagonist, in human plasma and urine by radioimmunoassay
35. Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: Bleeding, reversal, thrombocytopenia, and retreatment
36. In vitro and in vivo studies on the metabolism of tirofiban
37. Novel antiplatelet therapies for treatment of patients with ischemic heart disease: Inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor
38. Pharmacokinetics and pharmacodynamics of glycoprotein IIb-IIIa inhibitors
39. Nonenzymatic glycation of human blood platelet proteins
40. Attainment and maintenance of platelet inhibition through standard dosing of abciximab in diabetic and nondiabetic patients undergoing percutaneous coronary intervention
41. Tirofiban: A review of its use in acute coronary syndromes